ArticleKidney international2026
Endothelial prolyl hydroxylase 3 mitigates maladaptive inflammation to promote post-ischemic kidney repair.
Article in Kidney international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Localization of O₂‑sensing ADO‑RGS pathway components in mouse and human kidneys under normoxia, hypoxia and renal fibrosis.Pflugers Archiv : European journal of physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionAcute kidney injury (AKI) is a major health concern and well-established risk factor for the development of chronic kidney disease (CKD). Tissue hypoxia is a prominent feature of the injured kidney that shapes the biological behavior of parenchymal and immune cells. Endothelial cells have important immunomodulatory roles, but the impact of dysregulated oxygen sensing on their responses remains poorly understood.
methodsTo investigate the role of endothelial oxygen sensing in AKI, we leveraged a combination of conditional mouse strains, single cell analyses of mouse and human samples, and complementary in vitro models. Specifically, we examined the impact of endothelial-specific inactivation of prolyl hydroxylase (PHD)1 or PHD3 in post-ischemic kidneys (ischemia/reperfusion model) and subsequently assessed the contribution of hypoxia inducible factor (HIF) signaling in the setting of endothelial PHD3 loss using genetic and mechanistic approaches.
resultsAcross two independent human datasets, endothelial PHD3 upregulation emerged as a consistent AKI signature, highlighting its clinical relevance. Post-ischemic inactivation of endothelial PHD3, but not PHD1, leads to maladaptive kidney repair in mice, characterized by increased fibrosis and inflammation. scRNA-seq analysis of the post-ischemic endothelial PHD3-haplodeficient kidney showed an endothelial interferon-γ gene signature, resembling the responses seen in patients with severe AKI. In vitro, both loss- and gain-of-function experiments demonstrated that PHD3 regulated interferon-γ-responsive pro-inflammatory signatures in an HIF-dependent manner. Consistent with this, simultaneous deletion of aryl hydrocarbon receptor nuclear translocator, the obligatory binding partner for HIF-α, restored kidney repair in endothelial PHD3-deficient mice.
conclusionsOur findings identified endothelial PHD3 as a critical oxygen sensor that protected the kidney against maladaptive post-ischemic inflammation. By suppressing excessive interferon-γ-driven endothelial activation, PHD3 promoted tissue repair and limited the AKI-to-CKD transition, highlighting potential therapeutic avenues for mitigating disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.